{"transactions":[{"id":1973632,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-03T17:48:33.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":25000,"price":18.6121,"value":465302.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.37 to $18.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":330000,"source":{"system":"sec-edgar","filing":"0001209191-23-015850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919123015850/doc4.xml","form_type":"4"}},{"id":2033003,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T16:48:52.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":1106,"price":21.6892,"value":23988.2552,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $21.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":355000,"source":{"system":"sec-edgar","filing":"0001209191-23-006945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919123006945/doc4.xml","form_type":"4"}},{"id":2033002,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T16:48:52.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":23894,"price":21.2106,"value":506806.0764,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.65 to $21.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":356106,"source":{"system":"sec-edgar","filing":"0001209191-23-006945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919123006945/doc4.xml","form_type":"4"}},{"id":2067756,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T17:51:49.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":7610,"price":21.3106,"value":162173.666,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.98 to $21.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":380000,"source":{"system":"sec-edgar","filing":"0001209191-23-001275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919123001275/doc4.xml","form_type":"4"}},{"id":2067755,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T17:51:49.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":17390,"price":20.355,"value":353973.45,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":387610,"source":{"system":"sec-edgar","filing":"0001209191-23-001275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919123001275/doc4.xml","form_type":"4"}},{"id":2089665,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-12T16:56:46.000Z","date":"2022-12-08","kind":"sale","acquired":false,"shares":4358,"price":22.0767,"value":96210.2586,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.62 to $22.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":405000,"source":{"system":"sec-edgar","filing":"0001209191-22-060728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122060728/doc4.xml","form_type":"4"}},{"id":2096137,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-05T16:57:53.000Z","date":"2022-12-02","kind":"sale","acquired":false,"shares":5000,"price":21.5452,"value":107726.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.99 to $21.87 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":409358,"source":{"system":"sec-edgar","filing":"0001209191-22-059727","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122059727/doc4.xml","form_type":"4"}},{"id":2096136,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-05T16:57:53.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":240,"price":22.3375,"value":5361.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $22.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":414358,"source":{"system":"sec-edgar","filing":"0001209191-22-059727","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122059727/doc4.xml","form_type":"4"}},{"id":2096135,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-05T16:57:53.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":4760,"price":21.7213,"value":103393.388,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.24 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":414598,"source":{"system":"sec-edgar","filing":"0001209191-22-059727","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122059727/doc4.xml","form_type":"4"}},{"id":2125793,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-03T17:44:23.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":5000,"price":20.0138,"value":100069.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.045 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":419358,"source":{"system":"sec-edgar","filing":"0001209191-22-055596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122055596/doc4.xml","form_type":"4"}},{"id":2125792,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-03T17:44:23.000Z","date":"2022-11-01","kind":"sale","acquired":false,"shares":5000,"price":20.0417,"value":100208.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":424358,"source":{"system":"sec-edgar","filing":"0001209191-22-055596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122055596/doc4.xml","form_type":"4"}},{"id":2142242,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-05T16:32:00.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":5000,"price":20,"value":100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":429358,"source":{"system":"sec-edgar","filing":"0001209191-22-052756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122052756/doc4.xml","form_type":"4"}},{"id":2142241,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-05T16:32:00.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":5000,"price":20.063,"value":100315.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":434358,"source":{"system":"sec-edgar","filing":"0001209191-22-052756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122052756/doc4.xml","form_type":"4"}},{"id":2152681,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T16:00:12.000Z","date":"2022-09-21","kind":"other","acquired":false,"shares":1500000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 21, 2022, Canaan XI L.P. distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan Partners XI LLC, the general partner of Canaan XI L.P., representing each such partner's pro rata interest in the shares held by Canaan XI L.P.  On the same date, Canaan Partners XI LLC distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Act."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 21, 2022, Canaan XI L.P. distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan Partners XI LLC, the general partner of Canaan XI L.P., representing each such partner's pro rata interest in the shares held by Canaan XI L.P.  On the same date, Canaan Partners XI LLC distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Act."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P.  The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":6964301,"source":{"system":"sec-edgar","filing":"0000899243-22-031691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031691/doc4.xml","form_type":"4"}},{"id":2152680,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T16:00:12.000Z","date":"2022-09-21","kind":"sale","acquired":false,"shares":6106,"price":19.29,"value":117784.74,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.27 - $19.35, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P.  The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":8464301,"source":{"system":"sec-edgar","filing":"0000899243-22-031691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031691/doc4.xml","form_type":"4"}},{"id":2152679,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T16:00:12.000Z","date":"2022-09-21","kind":"sale","acquired":false,"shares":607497,"price":18.54,"value":11262994.38,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.27 - $19.26, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P.  The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":8470407,"source":{"system":"sec-edgar","filing":"0000899243-22-031691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031691/doc4.xml","form_type":"4"}},{"id":2154096,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T18:05:36.000Z","date":"2022-09-20","kind":"sale","acquired":false,"shares":2266,"price":20.1,"value":45546.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 - $20.15, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9077904,"source":{"system":"sec-edgar","filing":"0000899243-22-031605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031605/doc4.xml","form_type":"4"}},{"id":2154095,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T18:05:36.000Z","date":"2022-09-20","kind":"sale","acquired":false,"shares":146404,"price":19.5,"value":2854878.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 - $19.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9080170,"source":{"system":"sec-edgar","filing":"0000899243-22-031605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031605/doc4.xml","form_type":"4"}},{"id":2154094,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T18:05:36.000Z","date":"2022-09-19","kind":"sale","acquired":false,"shares":76725,"price":20.57,"value":1578233.25,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.22 - $21.07, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9226574,"source":{"system":"sec-edgar","filing":"0000899243-22-031605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031605/doc4.xml","form_type":"4"}},{"id":2154093,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T18:05:36.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":3722,"price":22.04,"value":82032.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.98 - $22.28, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9303299,"source":{"system":"sec-edgar","filing":"0000899243-22-031605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031605/doc4.xml","form_type":"4"}},{"id":2154092,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T18:05:36.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":111585,"price":21.53,"value":2402425.05,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.98 - $21.97, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9307021,"source":{"system":"sec-edgar","filing":"0000899243-22-031605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031605/doc4.xml","form_type":"4"}},{"id":2158448,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T19:53:20.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":3314,"price":23.73,"value":78641.22,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.55 - $24.01, inclusive.  The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9418606,"source":{"system":"sec-edgar","filing":"0000899243-22-031193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031193/doc4.xml","form_type":"4"}},{"id":2158447,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T19:53:20.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":47967,"price":22.79,"value":1093167.93,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $22.54 - $23.52, inclusive.  The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9421920,"source":{"system":"sec-edgar","filing":"0000899243-22-031193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031193/doc4.xml","form_type":"4"}},{"id":2158446,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T19:53:20.000Z","date":"2022-09-14","kind":"sale","acquired":false,"shares":384,"price":24.29,"value":9327.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.28 - $24.29, inclusive.  The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9469887,"source":{"system":"sec-edgar","filing":"0000899243-22-031193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031193/doc4.xml","form_type":"4"}},{"id":2158445,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T19:53:20.000Z","date":"2022-09-14","kind":"sale","acquired":false,"shares":105727,"price":23.68,"value":2503615.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.25 - $24.23, inclusive.  The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9470271,"source":{"system":"sec-edgar","filing":"0000899243-22-031193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031193/doc4.xml","form_type":"4"}},{"id":2158444,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T19:53:20.000Z","date":"2022-09-13","kind":"sale","acquired":false,"shares":1003,"price":25.01,"value":25085.03,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.00 - $25.06, inclusive.  The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9575998,"source":{"system":"sec-edgar","filing":"0000899243-22-031193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031193/doc4.xml","form_type":"4"}},{"id":2158443,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Julie Papanek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T19:53:20.000Z","date":"2022-09-13","kind":"sale","acquired":false,"shares":86644,"price":24.39,"value":2113247.16,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.00 - $24.99, inclusive.  The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":9577001,"source":{"system":"sec-edgar","filing":"0000899243-22-031193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000089924322031193/doc4.xml","form_type":"4"}},{"id":2158442,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T13:21:28.000Z","date":"2022-09-02","kind":"sale","acquired":false,"shares":5000,"price":23.8215,"value":119107.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.5200 to $24.1700 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":439358,"source":{"system":"sec-edgar","filing":"0001209191-22-050010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122050010/doc4.xml","form_type":"4"}},{"id":2165678,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-06T19:52:24.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":531,"price":23.7958,"value":12635.5698,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7500 to $23.8300 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":444358,"source":{"system":"sec-edgar","filing":"0001209191-22-048899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122048899/doc4.xml","form_type":"4"}},{"id":2165677,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-06T19:52:24.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":4469,"price":23.2094,"value":103722.8086,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7300 to $23.7100 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":444889,"source":{"system":"sec-edgar","filing":"0001209191-22-048899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122048899/doc4.xml","form_type":"4"}},{"id":2191941,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-08T20:03:28.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":5000,"price":20,"value":100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":449358,"source":{"system":"sec-edgar","filing":"0001209191-22-044898","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122044898/doc4.xml","form_type":"4"}},{"id":2191940,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-08T20:03:28.000Z","date":"2022-08-04","kind":"sale","acquired":false,"shares":5000,"price":20.0008,"value":100004.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":454358,"source":{"system":"sec-edgar","filing":"0001209191-22-044898","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122044898/doc4.xml","form_type":"4"}},{"id":2204569,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-20T18:17:52.000Z","date":"2022-07-18","kind":"sale","acquired":false,"shares":2600,"price":20.0004,"value":52001.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":459358,"source":{"system":"sec-edgar","filing":"0001209191-22-042764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122042764/doc4.xml","form_type":"4"}},{"id":2208630,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T21:14:57.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":800,"price":20,"value":16000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":463200,"source":{"system":"sec-edgar","filing":"0001209191-22-041994","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122041994/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-06"}},{"id":2208629,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T21:14:57.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":464000,"source":{"system":"sec-edgar","filing":"0001209191-22-041994","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122041994/doc4a.xml","form_type":"4/A","original_submission_date":"2022-07-06"}},{"id":2208626,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T21:14:23.000Z","date":"2021-11-03","kind":"gift","acquired":true,"shares":465000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by the Family Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":465000,"source":{"system":"sec-edgar","filing":"0001209191-22-041993","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122041993/doc5.xml","form_type":"5"}},{"id":2208625,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T21:14:23.000Z","date":"2021-11-03","kind":"gift","acquired":false,"shares":465000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the contribution of 465,000 shares to The Grant Family Delaware Trust (the \"Family Trust\"), of which the Reporting Person is the trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-041993","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122041993/doc5.xml","form_type":"5"}},{"id":2208622,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T19:52:04.000Z","date":"2022-07-08","kind":"sale","acquired":false,"shares":1242,"price":20,"value":24840.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Act\"), or for any other purpose."}],"balance_after":461958,"source":{"system":"sec-edgar","filing":"0001209191-22-041984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122041984/doc4.xml","form_type":"4"}},{"id":2211994,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-06T20:58:57.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":800,"price":20,"value":16000.0,"ownership":{"direct":false,"nature":"The Grant Family Delaware Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee."}],"balance_after":463200,"source":{"system":"sec-edgar","filing":"0001209191-22-041408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122041408/doc4.xml","form_type":"4"}},{"id":2211993,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-06T20:58:57.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":false,"nature":"The Grant Family Delaware Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee."}],"balance_after":464000,"source":{"system":"sec-edgar","filing":"0001209191-22-041408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122041408/doc4.xml","form_type":"4"}},{"id":2223069,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to buy Common Stock)","published_at":"2022-06-23T18:10:14.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":28700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12th of the total shares on each monthly anniversary, beginning on July 21, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":28700,"derivative":{"exercise_price":16.29,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":28700},"source":{"system":"sec-edgar","filing":"0001209191-22-039049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919122039049/doc4.xml","form_type":"4"}},{"id":2686634,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-02T20:52:57.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":148279,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Canaan XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held by Canaan XI, L.P. (\"Canaan LP\"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":148279},"source":{"system":"sec-edgar","filing":"0001209191-21-037460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919121037460/doc4.xml","form_type":"4"}},{"id":2686633,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-06-02T20:52:57.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":7328497,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Canaan XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held by Canaan XI, L.P. (\"Canaan LP\"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7328497},"source":{"system":"sec-edgar","filing":"0001209191-21-037460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919121037460/doc4.xml","form_type":"4"}},{"id":2686632,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2021-06-02T20:52:57.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 23, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act."}],"balance_after":63000,"derivative":{"exercise_price":16,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001209191-21-037460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919121037460/doc4.xml","form_type":"4"}},{"id":2686631,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-02T20:52:57.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":148279,"ownership":{"direct":false,"nature":"By Canaan XI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F5","text":"The number of securities reported reflects the 1 to 2.325 stock split of the Issuer's Common Stock and convertible preferred stock that was effected on May 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"The number of securities reported reflects the 1 to 2.325 stock split of the Issuer's Common Stock and convertible preferred stock that was effected on May 23, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The number of securities reported reflects the 1 to 2.325 stock split of the Issuer's Common Stock and convertible preferred stock that was effected on May 23, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held by Canaan XI, L.P. (\"Canaan LP\"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any."}],"balance_after":148279,"derivative":{"underlying":"Common Stock","underlying_shares":148279},"source":{"system":"sec-edgar","filing":"0001209191-21-037460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919121037460/doc4.xml","form_type":"4"}},{"id":2686630,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:52:57.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":13000,"price":16,"value":208000.0,"ownership":{"direct":false,"nature":"By Canaan XI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held by Canaan XI, L.P. (\"Canaan LP\"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any."}],"balance_after":10735645,"source":{"system":"sec-edgar","filing":"0001209191-21-037460","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919121037460/doc4.xml","form_type":"4"}},{"id":2686629,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:52:57.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":148279,"ownership":{"direct":false,"nature":"By Canaan XI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held by Canaan XI, L.P. (\"Canaan LP\"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any."}],"balance_after":10722645,"source":{"system":"sec-edgar","filing":"0001209191-21-037460","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919121037460/doc4.xml","form_type":"4"}},{"id":2686628,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Grant Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T20:52:57.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":7328497,"ownership":{"direct":false,"nature":"By Canaan XI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held by Canaan XI, L.P. (\"Canaan LP\"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any."}],"balance_after":10574366,"source":{"system":"sec-edgar","filing":"0001209191-21-037460","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919121037460/doc4.xml","form_type":"4"}},{"id":4303108,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-26T17:27:17.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier on (i) May 25, 2018, or (ii) the date of the 2018 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":8.59,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-035958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919117035958/doc4.xml","form_type":"4"}},{"id":4602625,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":116012,"kind":"person","name":"Grant Julie Papanek","position":1,"cik":"0001673237","reported_name":"Papanek Julie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-09-15T16:22:06.000Z","date":"2016-09-13","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal monthly installments over a three-year period from the vesting commencement date of August 10, 2016."}],"balance_after":24000,"derivative":{"exercise_price":12.88,"expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-16-141585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673237/000120919116141585/doc4.xml","form_type":"4"}}]}